FleuryBSP:FLRY3 -0.19%91 EV-to-FCF is 7.47 as of Jun. 30, 2026, which is 54% below its 10-year median of 16.22. GuruFocus rates BSP:FLRY3 with a GF Score™ of 91/100 and a GF Value™ of R$17.41 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, Fleury ranks better than 88.66% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fleury's Enterprise Value is R$11,772 Mil.
Fleury's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was R$1,576 Mil. Therefore, Fleury's EV-to-FCF for today is 7.47.
The historical rank and industry rank for Fleury's EV-to-FCF or its related term are showing as below:
BSP:FLRY3'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.15 Med: 16.22 Max: 44.04
Current: 7.48
During the past 13 years, the highest EV-to-FCF of Fleury was 44.04. The lowest was 6.15. And the median was 16.22.
BSP:FLRY3's EV-to-FCF is ranked better than 88.66% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.8
vs BSP:FLRY3: 7.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-30), Fleury's stock price is R$15.58.
Fleury's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was R$1.158. Therefore, Fleury's PE Ratio (TTM) for today is 13.45.
Fleury (BSP:FLRY3) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fleury's share price for today is R$15.58.
Fleury's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1.158.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fleury EV-to-FCF Related Terms
Fleury EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Fleury's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Fleury's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fleury's EV-to-FCF falls into.
Fleury's current Enterprise Value is R$11,772 Mil.
Fleury's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,576 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a EV-to-FCF of 7.47 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fleury and its competitors. This is 54% below median its historical median of 16.22. Over the past decade, Fleury's EV-to-FCF has ranged from 6.15 to 44.04. According to the industry distribution chart, Fleury ranks #11 out of 97 companies in the Medical Diagnostics & Research industry, placing it in the top 11.3%.
Is Fleury's EV-to-FCF too high?
Fleury's current EV-to-FCF of 7.47 is 54% below median its 10-year median of 16.22. Over the past 10 years, this metric has ranged from a low of 6.15 to a high of 44.04. The Medical Diagnostics & Research industry median EV-to-FCF is 22.80. Fleury's value of 7.47 is 67.2% below this industry median. Based on the distribution chart, Fleury ranks #11 out of 97 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fleury has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fleury's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #11 out of 97 companies for EV-to-FCF. This places Fleury in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 22.80. Fleury's value of 7.47 is 67.2% below this benchmark. Historically, Fleury's own EV-to-FCF has ranged from 6.15 to 44.04 over the past decade. While the company's 10-year median is 16.22 vs. the industry median of 22.80, Fleury has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.80, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current EV-to-FCF of 7.47 is 67.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current EV-to-FCF is 7.47, which is 54% below median its own 10-year median of 16.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$17.41, compared to a current price of R$15.58 — trading 10.5% below its estimated fair value. The current EV-to-FCF is 7.47, which is 54% below median its 10-year median of 16.22 and 67.2% below the Medical Diagnostics & Research industry median of 22.80. Fleury's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current EV-to-FCF is 7.47 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$15.58 is trading 10.5% below its estimated GF Value™ of R$17.41.
GuruFocus considers Fleury to be Modestly Undervalued.
Key valuation signals for BSP:FLRY3:
EV-to-FCF: 7.47 (54% below median its 10-year median of 16.22)
GF Value™: R$17.41 vs. price of R$15.58 (10.5% below fair value)
Industry Position: 67.2% below the Medical Diagnostics & Research median (#11 of 97)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
91GF Score
Get the complete analysis for BSP:FLRY3
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
